RDY Valuation

Dr Reddy's Laboratories Ltd

Add to Watchlist

Advanced Chart

13.020

+0.590(+4.750%)

Overview
Forecast
Valuation

RDY Relative Valuation

RDY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RDY is overvalued; if below, it's undervalued.

Historical Valuation

Dr Reddy's Laboratories Ltd (RDY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 15.04 is considered Undervalued compared with the five-year average of 21.49. The fair price of Dr Reddy's Laboratories Ltd (RDY) is between 19.46 to 26.01 according to relative valuation methord. Compared to the current price of 13.02 USD , Dr Reddy's Laboratories Ltd is Undervalued By 33.09%.

Relative Value

Fair Zone

19.46-26.01

Current Price：13.02

33.09%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.91

P/B

Median3y

3.65

Median5y

3.99

1.18

FCF Yield

Median3y

3.62

Median5y

3.15

Competitors Valuation Multiple

The average P/S ratio for RDY's competitors is 5.31, providing a benchmark for relative valuation. Dr Reddy's Laboratories Ltd Corp (RDY) exhibits a P/S ratio of 2.59, which is -51.32% above the industry average. Given its robust revenue growth of 14.99%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

RDY.N

Dr Reddy's Laboratories Ltd